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N E U R O S C I E N C E
Microglia become hypofunctional and release 
metalloproteases and tau seeds when phagocytosing 
live neurons with P301S tau aggregates
Jack H. Brelstaff1, Matthew Mason1, Taxiarchis Katsinelos1,2, William A. McEwan1,2, 
Bernardino Ghetti3, Aviva M. Tolkovsky1*, Maria Grazia Spillantini1*
The microtubule-associated protein tau aggregates in multiple neurodegenerative diseases, causing inflammation 
and changing the inflammatory signature of microglia by unknown mechanisms. We have shown that microglia 
phagocytose live neurons containing tau aggregates cultured from P301S tau mice due to neuronal tau aggregate- 
induced exposure of the “eat me” signal phosphatidylserine. Here, we show that after phagocytosing tau aggregate- 
bearing neurons, microglia become hypophagocytic while releasing seed-competent insoluble tau aggregates. These 
microglia express a senescence-like phenotype, demonstrated by acidic -galactosidase activity, secretion of para-
crine senescence-associated cytokines, and maturation of matrix remodeling enzymes, results that are corroborated 
in P301S mouse brains and ex vivo brain slices. In particular, the nuclear factor B–dependent activation of matrix 
metalloprotease 3 (MMP3/stromelysin1) was replicated in brains from patients with tauopathy. These data show that 
microglia that have been activated to ingest live tau aggregates-bearing neurons behave hormetically, becoming 
hypofunctional while acting as vectors of tau aggregate spreading.
INTRODUCTION
Aggregation of the protein tau from a soluble unfolded state to an 
insoluble,  sheet–enriched filamentous structure underlies numerous 
human neurodegenerative diseases known as tauopathies (1). These 
include Alzheimer’s disease (AD), various frontotemporal dementias, 
Pick’s disease, progressive supranuclear palsy (PSP), corticobasal 
degeneration, chronic traumatic encephalopathy, and argyrophilic 
grain disease. The presence of intraneuronal aggregates of tau best 
correlates with the neuronal cell death that is associated with the 
clinical signs and symptoms of disease (2). The mechanism of cell 
death in tauopathy remains unclear; however, several studies implicate 
microglia in non–cell-autonomous routes (3–5).
Microglia are the resident immune cells of the brain and, in 
neurodegeneration, become pathologically activated, leading to 
proliferation and release of cytotoxic cytokines. Microglia have high 
phagocytic potential and remove synapses during developmental 
pruning and disease via phosphatidylserine (PtdSer) (6). Recent 
evidence shows that microglia are also capable of aberrantly phago-
cytosing synapses and viable neurons in the adult mouse brain 
(7–9), and synapse loss is increased in AD (10). We have previously 
shown that inflammation is present in human mutant P301S tau 
mice (P301S tau) (11) and that live cultured dorsal root ganglion 
neurons (DRGn) from P301S tau mice display PtdSer on the external 
leaflet of their plasma membranes, which recruits cocultured 
microglia that phagocytose them while still viable (9). This process 
is accompanied by secretion of the opsonin milk fat globule epidermal 
growth factor 8 (MFGE8) and nitric oxide production and leads to 
the transfer of tau aggregates inside the phagocytosed neurons to 
the microglia (9). Microglia have also been shown to phagocytose 
extracellular tau and become activated to phagocytose neurons 
in a protein kinase C–dependent manner (4). These data impli-
cate microglia in the pathological loss of neurons and synapses 
in tauopathy by intensifying phagocytic activity to damaging 
levels.
Tau misfolds into distinct fibrillar forms depending on the 
specific tauopathy (12). Different filamentous forms of tau can 
template specific pathological conformations onto naïve monomers 
through a mechanism of prion-like spreading (13). Analysis of 
Braak stage progression suggests that misfolded tau is released as 
seeds through synaptic connections because anatomically connected 
regions progressively develop pathology (14). Microglia have also 
been implicated in the spreading of tau pathology (15) by releasing 
exosomes containing tau (15, 16). If microglia release tau seeds after 
phagocytosing either a tau aggregate–containing neuron or an 
extracellular tau released at a synapse, they could also act as vectors 
of tau spreading in the local environment.
Here, we report that in vitro microglia that have phagocytosed 
living neurons with insoluble filamentous tau aggregates contain 
tau foci and release insoluble tau aggregates into the conditioned 
medium (CM). Tau released from such microglia seeds new tau 
aggregates that are hyperphosphorylated in a reporter system consist-
ing of human embryonic kidney (HEK)–P301S-venus–expressing 
cells. Microglia cocultured with tau aggregate–containing neurons 
become hypophagocytic toward both latex beads and a second 
exposure to tau aggregate–containing neurons that expose the 
phagocytic signal PtdSer. Evidence for a hypophagocytic microglial 
phenotype in the brains of P301S mice was confirmed in ex vivo 
cerebral slice cultures incubated with latex beads. The microglia, 
recultured following coculture with P301S tau aggregate–containing 
neurons, also show an increase in senescence-associated -galactosidase 
(SA--gal) activity. Furthermore, microglia cocultured with aggre-
gated P301S tau-containing neurons secrete a unique signature of pro-
teins that differs from that of lipopolysaccharide (LPS)–stimulated 
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inflammatory microglia. Among these secreted proteins, the active 
form of matrix metalloprotease 3 (MMP3) is not only highly induced 
in microglia by coculture with tau aggregate–containing neurons 
but also increased in the brains of P301S tau transgenic mice and in 
brains of patients with tauopathies. Consistent with the paracrine 
signaling properties of the senescence-associated secretory phenotype 
(SASP), CM from cocultures of microglia and tau aggregate–bearing 
neurons increased SA--gal in naïve, monocultured microglia. Hence, 
microglia that have phagocytosed neurons containing tau aggregates 
enter a unique hypofunctional state that resembles aspects of 
senescence, including the capacity to induce local cellular dysfunction 
by paracrine signaling with soluble effectors.
RESULTS
Microglia that have phagocytosed P301S tau neurons 
containing tau aggregates release tau
DRGn cultures prepared from 5-month-old P301S tau (5M P301S) 
mice (17, 18) were cocultured for 4 days with wild-type microglia 
obtained from neonatal C57Bl6J mice (C57) to induce phagocytosis 
of live neurons containing filamentous tau aggregates as described 
previously (9). Neuronal tau aggregates that were prelabeled with 
pFTAA before addition of microglia (19) were visible as foci of 3 to 
5 m diameter and smaller puncta (Fig. 1A). CMs were assayed for 
human tau (htau) by enzyme-linked immunosorbent assay (ELISA) 
after 4 days from either monocultured neurons or microglia, from 
microglia cocultured with neurons, or from microglia reisolated 
after coculture (designated as “post”) and cultured alone for a further 
4 days (Fig.  1B). No measurable tau was detected in CM from 
monocultured 5M P301S DRGn containing tau aggregates, C57 
wild-type DRGn, or naïve microglia. However, tau (4.54 ± 0.49 pg/ml) 
was detected in the CM from 5M P301S DRGn-microglia cocultures 
(average ± SD, P = 0.012, one-sample t test) and continued to be 
present even when microglia were reisolated from the cocultures 
and cultured alone for a further 4 days (post) (8.4  ±  1.3 pg/ml, 
P  =  0.185 compared to 5M P301S DRGn-microglia cocultures 
unpaired t test), suggesting that the source of tau was specifically 
microglia that had phagocytosed neurons with tau aggregates (Fig. 1B). 
No significant differences in lactate dehydrogenase (LDH) release 
were detected in the CM across all conditions, demonstrating that 
tau was not released due to cell death and lysis [P = 0.069, one-way 
analysis of variance (ANOVA) across all conditions] (Fig. 1B).
To further confirm that microglia were the source of tau in the 
CM post-phagocytosis, PtdSer exposure on neurons was masked 
with annexin V (AnnV) before coculture (9). In the absence of 
AnnV, the proportion of P301S DRGn neurons containing htau 
(detected by the HT7 antibody) (% HT7 positive/III-tubulin–positive 
neurons) was significantly reduced ~2-fold when cocultured with 
microglia (P = 0.0048, repeated-measures ANOVA), but this loss 
was prevented by addition of AnnV (P = 0.0309 versus without AnnV, 
P = 0.378 versus naïve) (Fig. 1C). In keeping with a requirement for 
the engulfment of P301S DRGn for tau release by microglia, tau 
(10 ± 4.8 pg/ml) was detected in the CM of cocultured 5M P301S 
DRGn and microglia, but no tau was detected in the CM from 
cocultures when phagocytosis and loss of tau-positive neurons 
were prevented by adding AnnV (P = 0.0225 comparing ± AnnV, 
one-sample t test) (Fig. 1C). Thus, microglia that have phagocytosed 
tau aggregate–bearing DRGn are the source of tau released into 
the CM.
Tau in the CM is insoluble and seeds tau aggregation
To investigate whether released tau is monomeric or remains as 
larger-order aggregates similar to those found in the neurons from 
5M P301S mice (17, 19), tau in the CM was solubilized with SDS 
(5%), and the preparation was filtered through a 0.2-m cellulose 
acetate membrane (presoaked in 5% SDS to eliminate soluble 
oligomers) under vacuum, a method that traps insoluble tau aggre-
gates from AD brains (20). Sarkosyl-insoluble tau aggregates from 
the spinal cord of 5M P301S mice (9, 18) were used as a positive 
control. CM from cocultured 5M P301S DRGn and microglia 
contained tau species large enough to be captured on the membrane 
(Fig. 2A), but no tau was detected in CM from monocultures of 
microglia, 5M P301S DRGn, or 2M P301S DRGn [which do not 
contain aggregated tau (17)] or from cocultured 2M P301S DRGn 
and microglia. To further demonstrate that the tau coming from the 
coculture CM and trapped on the filter was insoluble, each individual 
filtrate was cut in half as illustrated in the scheme labeled refiltra-
tion process in Fig. 2A: One-half was treated with 70% formic acid 
(FA), which solubilizes tau aggregates (19), dialyzed to remove FA, 
and refiltered. Extracts from the untreated half of the filtrate, which 
was only minced and soaked in 5% SDS, were also refiltered. 
FA-treated samples showed no signal, whereas the extracts from the 
minced samples were still trapped on the new membrane (Fig. 2A), 
indicating that the tau assemblies trapped on the membrane are 
insoluble aggregates.
To assay whether tau released from microglia into the CM has 
aggregation-inducing properties, we used the HEK-P301S-venus 
cell reporter system (21). HEK-P301S-venus cells were incubated with 
CM for 24 hours, fixed, and immunostained with AT8 (anti–phospho- 
serine-202/205 antibody) to detect hyperphosphorylated tau or 
with MC1, which is a conformational antibody that solely detects 
misfolded tau (9, 22, 23). Addition of heparin-tau aggregates was 
used as a positive control. CM from cocultured 5M P301S DRGn and 
microglia seeded AT8- and MC1-positive aggregates (“naïve” indicates 
untreated microglia; Fig. 2B), whereas CM from monocultures of 
C57 or P301S DRGn or 5M C57 DRGn cocultured with microglia 
showed no seeding capability. To further determine the characteris-
tics of the tau seeds released into CM, the CM was ultracentrifuged 
at 100,000g for 30 min to separate soluble oligomeric species from 
insoluble aggregates. The pellet was resuspended to the original 
volume of the CM, and both fractions were added to HEK-P301S-
venus cells for 4 days in the presence of Lipofectamine to enhance 
seed uptake (21). The pellet fraction retained a similar aggregation 
activity to that of whole CM (P = 0.662, Friedman test), whereas the 
supernatant produced significantly fewer foci (P = 0.0429, Friedman 
test) (Fig. 2C, quantified in D). Thus, microglia that have phagocytosed 
neurons with tau aggregates release tau as species that are competent 
to seed insoluble tau aggregates in recipient cells.
Reisolated microglia from P301S tau neuron  
cocultures are hypophagocytic
We next investigated whether and how phagocytosis of neurons 
with tau aggregates affects microglial function. To test their phago-
cytic capacity, microglia were reisolated from cocultures with 5M 
P301S DRGn and were transferred to a new monoculture of 5M 
P301S DRGn. While coculture with naïve, noncocultured C57 
microglia caused a significant loss of tau neurons (P = 0.0013, one-way 
ANOVA), no significant loss of tau aggregate–containing neurons 
was detectable in coculture of reisolated C57 microglia (P = 0.9903, 
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one-way ANOVA) (Fig. 3A) (representative images of HT7- and 
III-tubulin–immunostained neurons from 5M P301S before and 
after coculture with microglia are shown in fig. S1). The loss of 
phagocytic capacity was unlikely to be due to the changed culture 
conditions between first and second exposure as microglia isolated 
from coculture with 5M C57 DRGn and added to 5M P301S DRGn 
did not show a decrease in phagocytic capacity (25.7 ± 5.8% reduction 
in the number of P301S DRGn with htau upon exposure to naïve 
microglia, 18.5 ± 4.5% reduction after adding microglia reisolated 
from cocultures with 5M C57 DRGn, means ± range of two inde-
pendent 5M P301S DRGn preparations). These results thus indicate 
that following ingestion of DRGn containing tau aggregates, the 
microglia become hypophagocytic and unable to ingest other DRGn 
with tau aggregates.
Phagocytosis of 5M P301S DRGn is dependent on the specific 
exposure of the phagocytic signal PtdSer on their membranes (9). 
To investigate whether the inhibition of microglial phagocytosis 
due to exposure to living P301S DRGn was an independent property 
acquired by the microglia, reisolated microglia were incubated with 
carboxylate-modified latex beads. Similar to the suppressed phago-
cytosis after exposure to 5M P301S DRGn, microglia reisolated from 
5M P301S DRGn-microglia cocultures phagocytosed significantly 
fewer beads than microglia reisolated from 5M C57 DRGn-microglia 
cocultures (P = 0.0239, one-way ANOVA with repeated measures) 
or nontreated naïve microglia (P = 0.007), which had equivalent 
bead uptake to the microglia reisolated from 5M C57 DRGn- 
microglia cocultures (P = 0.1507) (Fig. 3B, quantified in C). In 
contrast to the suppression of phagocytosis induced by the coculture 
of microglia with 5M P301S DRGn, exposure to heparin-tau aggre-
gates increased bead phagocytosis significantly (P ≤ 0.0001), suggest-
ing that it was the ingestion of the neurons containing tau aggregates, 
and not the exposure to aggregated tau, that causes this hypo-
functionality. Exposure to monomeric tau also appeared to increase 
average bead uptake, but the increase was not significant (n.s.) 
(P  =  0.5487). Exposure of monocultured microglia to PtdSer 
liposomes, to mimic the PtdSer exposure on 5M P301S DRGn, 
caused a similar bead uptake to naïve, monocultured microglia 
(P = 0.557) and was significantly higher compared to the uptake by 
microglia that had been reisolated from 5M P301S DRGn-microglia 
cocultures (P = 0.0139). These results indicate that the hypophago-
cytosis by microglia reisolated from 5M P301S DRGn-microglia 
cocultures was not related to PtdSer signaling. LPS, which was added as 
a positive control for the induction of microglial phagocytosis, increased 
bead uptake by the microglia by about twofold compared to the uptake 
by naïve, monocultured microglia (P = 0.028), similar to the uptake 
induced by monomeric and heparin-tau. Thus, PtdSer exposure is 
necessary for the phagocytosis of 5M P301S DRGn by microglia but 
is not sufficient to cause microglia to become hypophagocytic.
Fig. 1. Microglia that have phagocytosed P301S DRGn containing tau aggregates release htau into the CM. (A) Tau aggregates in 5M P301S DRGn prelabeled with 
pFTAA are transferred to microglia after phagocytosis. Microglia were purified after 4 days of coculture, replated, and imaged live. Left: Fluorescence and phase. Right: 
Fluorescence only. Arrows, pFTAA-positive tau foci. (B) htau is only released into the CM when 5M P301S DRGn and microglia are cocultured. Human transgenic tau was 
detected specifically by ELISA after 4 days (P = 0.012, versus all monocultures and coculture of microglia with 5M C57 neurons, one-sample t test). Tau is released over a 
further 4 days by microglia reisolated from 5M P301S DRGn cocultures (post) (P = 0.185 versus original coculture CM, unpaired t test). No tau is detected in CM from 
monocultures of 5M P301S or C57 DRGn or C57 microglia or from 5M C57 DRGn-microglia cocultures. Lactate dehydrogenase (LDH) activity is not significantly different 
across all conditions, indicating that released tau is not due to lysed cells (P = 0.069, one-way ANOVA). N = 3 to 4 independent experiments, means ± SD. (C) Release of tau 
requires phagocytosis by microglia. The number of htau-positive 5M P301S DRGn (% HT7/III-tubulin) is reduced after coculture with C57 microglia (green triangles, 
P = 0.0048, repeated-measures ANOVA), commensurate with an increase in tau in the CM (red circles, P = 0.0225, one-sample t test). Blocking phagocytosis by masking 
PtdSer with AnnV prevents neuronal loss (green triangles, n.s. versus P301S DRG, P = 0.0309 versus C57 microglia, repeated-measures ANOVA). AnnV also prevents the 
release of tau into the CM (red circles, n.s. versus P301S DRG). N = 4 independent experiments, means ± SD.
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Microglia in cerebral slices from P301S mice are 
hypophagocytic toward latex beads
To determine whether the hypophagocytic phenotype observed in 
our coculture systems occurred in vivo in the brain, sagittal slice 
cultures from 5M C57 and P301S mice were incubated with latex 
beads using a method previously described (24). Abundant pFTAA 
staining was observed within the cortex of the 5M P301S mice, 
which was absent in the same brain region in 5M C57 mice (Fig. 3D, 
small panels). Over a 3-hour incubation period, microglia within 
the slice cultures phagocytosed latex beads present in the media, as 
determined by fluorescence colocalization of Iba1 and latex beads. 
Similar to our in vitro findings, microglia in the cortex of 5M P301S 
mice, where pFTAA-positive tau aggregates are found, phagocytosed 
significantly fewer latex beads than microglia in 5M C57 mice 
(Fig. 3D, large panels; fig. S2A shows a maximum projection confocal 
image). Results are quantified in Fig. 3E (P = 0.0404, Mann-Whitney 
Fig. 2. Microglia cocultured with 5M P301S DRGn release insoluble tau aggregates capable of seeding. (A) Insoluble tau in the CM is captured on a filter trap 
(detected with the anti–htau antibody HT7). Top left filter, top row: No tau in CM from monocultures of DRGn (5M C57 and 2M P301S, which do not contain tau aggre-
gates, and 5M P301S) or cocultures of C57 microglia with 2M P301S DRGn. Top left filter, bottom row: htau in CM from cocultures of microglia with 5M P301S DRGn, with 
spinal cord extracts as positive controls. Bottom right filter: Refiltration of captured tau solubilized in formic acid (FA+) leads to loss of signal, but minced samples (FA−) 
retain signal. A scheme of the refiltration procedure is also shown (top right). (B) Tau in CM seeds new aggregates in the reporter system HEK-P301S-venus cells. The 
tau-seeded aggregates contain hyperphosphorylated and conformationally altered tau as shown by AT8 and MC1 antibody staining (red). Alexa Fluor-647–conjugated 
phalloidin (green) was used to outline the cell perimeter. Nuclei were stained by DAPI (blue). (C and D) Aggregated P301S-venus foci are obtained with the 100,000g 
pellet but not the supernatant of CM after ultracentrifugation (P = 0.0429, Friedman test). Representative images and quantification of fractionated CM seeded aggregation 
in HEK-P301S-venus cells. Lipofectamine was added to increase the efficiency of the uptake. The number of aggregates per 100 cells is quantified in (D). N = 3 independent 
cultures of neurons used for CM preparations, means ± SD.
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U test). Thus, in the brain, microglia within the same region of 
aggregated tau–bearing neurons are hypophagocytic toward latex 
beads.
Hypophagocytic microglia activate senescence-associated 
acidic -galactosidase
Since we had observed a loss of microglial function due to coculture 
with tau aggregate–containing neurons and pathological tau has 
been associated with deleterious microglial cellular senescence in a 
mouse model of tauopathy and in AD (25, 26), we investigated 
whether senescence was induced in these hypofunctional microglia. 
We first tested whether microglia reisolated from coculture with 
5M P301S DRGn exhibited SA--gal activity. There were significantly 
more -galactosidase–positive microglia in cultures reisolated from 
5M P301S DRGn cocultures compared to microglia reisolated from 
cocultures with 5M C57 DRGn (~3-fold, P = 0.0168, one-way 
ANOVA) or naïve, monocultured microglia (P = 0.0025) (Fig. 4A, 
quantified in B). As a positive control for the assay, we exposed 
Fig. 3. Microglia reisolated from 5M P301S DRGn cocultures or those in 5M P301S brain slices are hypophagocytic. (A) Naïve C57 microglia (concave in cartoon) 
phagocytose P301S DRGn, whereas microglia reisolated from 5M P301S DRGn-microglia cocultures (sunburst shape) are not phagocytic toward a second culture of 5M 
P301S DRGn (5M P301S DRGn alone versus P301S DRGn with naïve C57 microglia, P = 0.0013, versus P301S DRGn reisolated C57 microglia, P = 0.9903, one-way ANOVA). 
N = 3 independent P301S DRGn cultures for the first or second cocultures, means ± SD. (B and C) Microglia reisolated from cocultures with 5M P301S DRGn show a significant 
reduction of latex bead uptake compared to naïve (untreated) microglia (naïve, P = 0.007) or microglia reisolated from coculture with 5M C57 DRGn (P = 0.0239, repeated-measures 
one-way ANOVA); treatment of naïve microglia with PtdSer liposomes does not reduce bead uptake (PtdSer, n.s.), while treatment with heparin-assembled tau significantly 
stimulates bead uptake (Hep htau, P < 0.0001). Quantification is shown in (C). N = 3 independent preparations of neurons or microglia exposed to the treatments are 
indicated, means ± SD. (D and E) Brain slices (130 m) from 5M C57 or 5M P301S mice were exposed to latex beads for 3 hours, fixed, and stained for microglia (Iba1, green) 
to quantify the number of ingested beads (D) (large panels). Matching slices were stained with pFTAA to demonstrate tau aggregates (D) (small panels). Microglia in 
sections from brains of 5M P301S mice have a significantly reduced phagocytic capacity compared to 5M C57 mice (P = 0.0404, Mann-Whitney U test). The phagocytic 
index is displayed in (E). N = 3 independent experiments per genotype, means ± SD.
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naïve microglia to bleomycin, which is a well-established inducer of 
cellular senescence (27). Bleomycin (50 g/ml, 12 hours) up-regulated 
acidic -galactosidase activity about eightfold compared to microglia 
cocultured with 5M C57 DRGn. The presence of elevated -galactosidase 
in vivo was confirmed in that an increase in the overall intensity of 
SA--gal staining was observed in cortical sections from 5M P301S 
mice compared to sections from the same regions of 5M C57 control 
mice (fig. S2B). The existence of a senescent-like phenotype was 
further supported by the significant presence of nuclear p19ARF 
immunostaining in microglia reisolated from coculture with 5M 
P301S DRGn but not in microglia reisolated from cocultures with 
5M C57 DRGn (Fig. 4C, quantified in D). Thus, microglia that have 
phagocytosed or have been cocultured with 5M P301S DRGn with 
tau aggregates not only are hypophagocytic but also appear to have 
acquired a senescence-like state.
Hypophagocytic microglia release a specific senescence-like 
protein profile highly enriched in MMP3
To investigate whether microglia that have phagocytosed 5M P301S 
DRGn produce signals that may account for their hypofunctional 
post-phagocytic state, we screened the CM for the abundance of 
111 mouse proteins (consisting of cytokines, chemokines, growth factors, 
and matrix-modifying proteases) across multiple treatment conditions 
using the membrane-based Proteome Profiler Cytokine array (rep-
resentative images of results from membranes of each condition are 
shown in fig. S3A, and fig. S3B shows quantification of relative inten-
sities normalized to internal standards across the entire membrane). 
DRGn monocultures from 5M C57 mice or 5M P301S mice 
produced no detectable cytokines, but naïve microglial monocul-
tures produced a basal secretory profile that includes CCL2, CCL6, 
Chemerin, IGFBP-6, mouse colony-stimulating factor 1 (mCSF1), 
Osteopontin, Serpin E1, and vascular endothelial growth factor 
(VEGF). LPS treatment of naïve microglia, used to profile an 
inflammatory phenotype, induced a classical inflammation–associated 
profile including high levels of tumor necrosis factor– (TNF) 
secretion. In contrast, no proinflammatory cytokines such as TNF 
were detected in CM from cocultures of microglia with 5M P301S 
DRGn. Instead, a different profile of proteins was released.
Submitting the full array of proteins to STRING analysis (28) 
identified a network of MMP3 and 14 putative partners (MMP3, 
MMP9, CXCL2/MIP2, CXCL1/KC, MMP2, VEGF, Endostatin, IGFBP3, 
Pentraxin2, CXCL10, CCL5/Rantes, CXCL5, CXCL9, CXCL13, and 
CCL20) (Fig. 5A). Of these, CXCL5, CXCL9, CXCL13, and 
CCL20 showed no secretion across any of the conditions assayed 
and were therefore excluded from further analysis. The relative 
abundance values and row z scores for the remaining 11 proteins 
are shown in Fig. 5B. Six of the proteins listed in bold have been 
previously associated with the SASP profile (29). Principal compo-
nents analysis (PCA) of the 11 proteins showed that the subset of 
proteins released by microglia cocultured with 5M P301S DRGn 
formed a unique group, distinct from LPS-treated microglia or 
those cocultured with C57 DRGn or 2M P301S DRGn (Fig. 5C). 
This was further corroborated by the biweight midcorrelation 
analysis (Fig. 5D).
Fig. 4. Microglia reisolated from 5M P301S DRGn cocultures display increased SA--gal activity. (A and B) The senescence marker SA--gal is significantly increased 
in microglia reisolated from cocultures with 5M P301S DRGn compared to microglia reisolated from cocultures with 5M C57 DRGn (post P301S DRGn versus post C57 
DRGn, P = 0.0168) or naïve, monocultured microglia (naïve, P = 0.0025, one-way ANOVA and Sidak post hoc). The senescence inducer bleomycin is used as a positive 
control. Quantification of -gal is shown in (B). N = 3 independent cultures of neurons or microglia, means ± SD. (C and D) The senescence marker P19ARF (red) undergoes 
significant nuclear translocation (arrows) in microglia (white; lectin IB4) following coculture with 5M P301S DRGn compared to naïve, monocultured microglia (P = 0.0098) 
and microglia cocultured with 5M C57 DRGn (P = 0.0482, one-way ANOVA and Sidak post hoc). The senescence inducer bleomycin is used as a positive control. Nuclear 
intensity data are quantified in (D). N = 3 independent experiments, means ± SD.
Brelstaff et al., Sci. Adv. 2021; 7 : eabg4980     20 October 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
7 of 15
To examine whether phagocytosis capacity and SA--gal are 
related to ingestion of neurons with tau aggregates or to other 
signals that arise in the CM as a result of phagocytosis, we exposed 
naïve microglia to CM isolated from cocultures of 5M P301S or 5M 
C57 DRGn with microglia or monocultures of these neurons (Fig. 5E, 
quantified in F). CM from cocultured 5M P301S DRGn and microglia 
induced a significant number of -galactosidase–positive microglia, but 
very few positive microglia were detected under any other culture 
condition. Bleomycin induced -galactosidase in 87.7 ± 14.6% of 
the microglia. CM from cocultures of 5M P301S DRGn and microglia in-
duced -galactosidase in 58.6 ± 17.6%, P < 0.0001 against 5M P301S 
or 5M C57 DRGn monocultures or cocultured 5M C57 neurons and 
microglia (N  =  5 independent preparations of CM, means  ±  SD, 
one-way ANOVA with Bonferroni post hoc correction). It remains 
to be defined whether this effect is induced in microglia due to 
ingestion of tau-containing neurons and/or their dissolution or to 
other proteins coingested with tau that were released into the medium. 
Regardless, this effect of microglia-released proteins is in keeping 
with the SASP that we observe.
MMP3 is up-regulated in the CM of cocultured 5M P301S 
DRGn and microglia and brains of P301S mice and  
human tauopathies
Because MMP3 was prominently up-regulated under the 5M P301S 
DRGn-microglia coculture condition and was attributed with one 
of the highest weight coefficients for PC1 (determined by the loading 
plot analysis presented in fig. S3C), we examined whether its abundance 
was also increased in mouse and human brains associated with 
tauopathies. A study of MMP3 expression in the frontal cortex of 
5M C57, 2M P301S, and 5M P301S mice by immunoblotting 
showed two bands corresponding to the inactive zymogen (pro form) 
and active (mature) MMP3 (30). Both the pro and active forms were 
present in wild-type mouse brain, but there was a highly significant 
conversion from the inactive to the active form in 5M P301S mice 
(P < 0.001, one-way ANOVA) (Fig. 6, A and B). In the 2M P301S 
mouse brain, there was no significant increase (P = 0.9120) (Fig. 6B). 
To investigate whether this up-regulation of MMP3 was present in 
human disease, tissue lysates from the frontal cortex of nondemented 
controls and patients with Frontotemporal dementia and Parkin-
sonism linked to chromosome 17 (FTDP-17T) with +3 or P301L 
MAPT mutations, or Pick’s disease, or from the midbrain of pa-
tients with PSP were immunoblotted for MMP3 (Fig. 6, C and D). 
Frontotemporal dementia (FTD) with TDP-43 pathology due to a 
C9orf72 expansion mutation was included to investigate whether 
MMP3 up-regulation is specific to pure tauopathies. The amount 
of active MMP3 was barely detected in extracts from control brains, 
but there was a substantial increase in the active/mature form in all 
the samples from neurodegenerative diseases: FTDP-17T with the +3 
and the P301L mutations were elevated 4.7-fold (P = 0.013) and 
4.5-fold (P = 0.043), respectively (ANOVA P = 0.04, two-tailed t test 
compared to control), while the ratios were slightly lower for C9orf72 
(1.78-fold, P = 0.003), PSP (2.45-fold, P = 0.019), and Pick’s disease 
(3.07-fold, P = 0.025) (ANOVA P = 0.012, two-tailed t test compared 
to control) (Fig. 6D). Hence, active MMP3 is a candidate marker of 
advanced tauopathies and at least one related form of dementia.
NFB regulates MMP3 expression
Previous studies have implicated the nuclear factor B (NFB) 
signaling pathway in the regulation of several of the proteins that we 
had identified in the CM from 5M P301S DRGn-microglia cocultures 
(31). Submission of the 11 proteins shown in Fig. 5B to the open-source 
gene set enrichment analysis database Enrichr (32) showed that 8 of 
these proteins, including MMP3, were predicted to be under the 
transcriptional control of NFB1, and 4 proteins were predicted to 
be under the transcriptional control of RelA (NFB p65 subunit) 
(Fig. 6E). We performed staining of brain sections from 5M C57 
and P301S mice with an anti–phospho-Ser536-NFB antibody to 
determine whether NFB signaling could be involved in the behavior 
of microglia in the mice. Abundant staining for phospho-Ser536-NFB 
that colocalized with microglia (detected by Iba1 staining) was 
observed in brain sections from P301S mice, whereas few mi-
croglia showed staining above background in sections from C57 
mice (Fig.  6,  F  and G). To further investigate whether NFB 
controls the production of MMP3 in our experimental paradigm, 
microglia were preincubated with the NFB pathway inhibitor 
BAY11-8072 (33) for 1 hour, after which they were cocultured with 
5M C57 or 5M P301S tau DRGn. CM was collected after 24 hours, 
and MMP3 was measured by ELISA. BAY11-8072 significantly 
reduced the amount of MMP3 in the CM from 5M P301S DRGn- 
microglia cocultures (P < 0.0001, two-way ANOVA with Tukey 
post hoc) (Fig. 6H). BAY11-8072 induced no change in the amount 
of MMP3 detected in 5M C57 DRGn-microglia cocultures. To 
investigate whether MMP3 secretion induced by 5M P301S tau 
DRGn in microglia was due to phagocytosis of the neurons, phago-
cytosis was prevented by preincubating the neurons with AnnV. Unlike 
BAY11-8072, AnnV blockade of phagocytosis did not reduce the 
production of MMP3 (n.s. compared to no 5M P301S DRG addi-
tions), indicating that phagocytosis-related hypofunctionality and 
NFB-dependent MMP3 production are activated by different effec-
tors emanating from the 5M P301S DRGn. These results show that 
while hypofunctionality is a consequence of the physical act of 
phagocytosis linked to PtdSer, MMP3 activation appears to 
depend on additional signals that are PtdSer-independent, in keep-
ing with the induction of SA--gal obtained when microglia were 
exposed to CM from cocultures of microglia with 5M P301S DRGn 
(Fig. 5, E and F).
DISCUSSION
Inflammation and microgliosis are a common feature of many neuro-
degenerative diseases, and microglial phagocytosis is suggested to 
be highly important in disease pathogenesis with the discovery of 
phagocytosis genes as genetic risk factors in AD (34). Here, we 
report that after phagocytosis of neurons with P301S tau aggregates, 
microglia release forms of tau that can seed new tau aggregates. On 
a population level, microglia become hypophagocytic, and they display 
several elements of senescence, including senescence-associated acidic 
-galactosidase activity and release of senescence-associated proteins, 
some of which are under NFB transcriptional control. It remains 
to be resolved whether the expression of senescent markers, the 
onset of a hypophagocytic phenotype, and the capacity for paracrine- 
mediated dysfunction are responses unique to microglia that have 
ingested tau aggregate–containing neurons or whether other microglia 
within the coculture undergo these phenotypic transitions independently 
of direct phagocytosis. In the latter case, the self-amplification of 
tau aggregation and microglial dysfunction could be extensive. A 
scheme illustrating how these events might lead to a vicious cycle of 
neurodegeneration is shown in Fig. 7.
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Our data show that microglia that have phagocytosed neurons 
with insoluble tau aggregates not only maintain these aggregates for 
several days but also expel aggregates capable of seeding tau aggre-
gation. Ingestion of neurons with tau aggregates was necessary for 
tau to appear in the medium since AnnV prevented phagocytosis of 
P301S neurons and also prevented tau release in cocultures of P301S 
DRGn and microglia, so tau release is unlikely to be a result of neuronal 
cell death induced outside the microglia or other factors in the culture 
environment. Our data showing an extended period of tau release 
are in agreement with a study where microglia isolated from adult 
Fig. 5. Microglia cocultured with 5M P301S DRGn secrete a unique protein profile. (A) Functional interaction network between the 11 proteins identified by STRING 
analysis. (B) Comparative heatmap analysis of protein expression of a family of proteins that are highly enriched in CM from 5M P301S DRGn-microglia cocultures or CM 
from microglia reisolated from cocultures with 5M P301S DRGn, but not in naïve, monocultured microglia or those cocultured 5M C57 DRGn or 2M P301S DRGn (with no 
filamentous tau aggregates). Previously published SASP members are in bold. (C) PCA plot of proteins presented in (A) (means ± SD, N = 3 independent experiments). 
(D) Biweight midcorrelation matrix of the PCA data showing a strong negative correlation between the condition of coculture of microglia with 5M P301S DRGn and all 
other experimental conditions except for microglia reisolated from cocultures with the 5M P301S DRGn. (E and F) Microglia treated with conditioned medium (CM) from 
cocultured 5M P301S DRGn and microglia significantly activate the senescence-associated marker -galactosidase activity compared to monocultures or microglia cocultured 
with 5M C57 DRGn (P = 1 × 10−5 versus naïve, C57 DRG, or P301S DRG, one-way ANOVA with Bonferroni post hoc correction). Data are quantified in (F). Bleomycin is used 
as a positive control. N = 5 independent experiments, means ± SD.
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rTg4510 mouse brains or AD brains also released tau over several 
days that was capable of seeding tau aggregation in a fluorescence 
resonance energy transfer–based biosensing cell assay (35). In the 
same study, inflammatory stimuli failed to increase the release of 
tau seeds from microglia, and LPS failed to induce the same 
secretome profile as that released from microglia cocultured with 
5M P301S DRGn, so perhaps, microglia with senescent phenotypes 
similar to those that we demonstrate here are those most prone to 
release tau seeds.
Microglia have previously been implicated as vectors of tau 
spreading in vivo through exosomes in mouse models with focal 
viral delivery of tau–green fluorescent protein (16). However, no 
filamentous or misfolded tau was detected in these experiments, so 
it remains to be shown whether tau would be released by microglia 
Fig. 6. MMP3 is converted to its active form in transgenic P301S mice and human neurodegenerative disease and is under transcriptional control of NFB. 
(A) Immunoblot of pro and active MMP3 expression in the frontal cortex of 5M C57 wild-type and 2M and 5M P301S transgenic mouse brains. (B) Ratio of active/pro forms 
of MMP3 showing that significantly more active MMP3 is expressed in the brains of 5M P301S mice (5M C57 versus 5M P301S P = 0.001, 2M P301S versus 5M P301S, 
P = 0.001; one-way ANOVA). N = 3 to 4 independent experiments, means ± SD. (C) MMP3 expression in the frontal cortex of controls, +3 and P301L mutant FTDP-17T 
cases, FTD with C9orf72 mutation cases, Pick’s disease, and midbrain from PSP cases. (D) Ratio of active MMP3/GAPDH intensities showing greater active MMP3 expression 
in neurodegenerative disease versus healthy control (Control versus +3 FTD, P = 0.0125; Control versus P301L, P = 0.0428; Control versus C9orf72, P = 0.0023; Control 
versus PSP, P = 0.0187; Control versus Pick’s, P = 0.0244; Student’s t test per blot). N = 3 to 4 independent experiments, means ± SD. (E) The number of proteins identified 
in the transcriptional regulation network using the Enrichr program; the shaded bar denotes −log10 transformation of adjusted P values that were computed by Fisher’s 
exact test within Enrichr. (F and G) NFB phosphorylated at Ser536 (red) is increased in P301S mouse brainstem (F) (pFTAA, green) and enriched in microglia as shown by 
colocalization with Iba1 (Iba, green, colocalization in yellow). (H) Treatment of microglia with the NFB pathway inhibitor BAY11-8072 significantly prevents the expression 
of MMP3 in cocultures of P301S aggregate-containing neurons and microglia. BAY11-8072 was added for 24 hours. AnnV masking of Ptdser over the same period does 
not prevent MMP3 production (P = 10−5, two-way ANOVA and Tukey post hoc), means ± SD.
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via exosomes if it were highly aggregated, as is the case here. 
Although tau aggregate pathology is thought to develop along 
synaptically connected routes through neuronally released tau seeds 
(14, 36), evidence for lateral spread of tau has been reported (37). 
Thus, it is possible that microglia surrounding neurons with tau 
pathology could act as sources of tau seeds, especially after PtdSer- 
dependent phagocytosis of tau aggregate–containing neurons or 
synapses that display PtdSer (6). It is interesting that the presence of 
filamentous aggregated tau inside microglia in human tauopathy 
cases is a rare event (38), despite well-described cases of tau pathology 
in astrocytes and oligodendrocytes (39). It is possible that microglia 
have a more efficient means of degrading or expelling tau aggre-
gates (40) than astrocytes or oligodendrocytes. Another possibility 
is that microglia with tau aggregates fragment and die due to acqui-
sition of a senescent phenotype (26), thereby releasing tau seeds. 
However, there was no noticeable microglial death in our cocultures 
based on sequential micrographs taken over the 4-day coculture 
period or in the study of Hopp et al. (35), so the mechanism of tau 
aggregate release remains to be identified.
The present data demonstrate that microglia show hormetic 
behavior: Having been activated to engulf neurons with tau aggre-
gates, the community of microglia become hypophagocytic and 
show signs of senescence. Exposure to tau per se is unlikely to be the 
cause of the functional sequelae because of the following: (i) Blocking 
phagocytosis with AnnV also blocked the release of tau seeds 
(Fig. 1C); (ii) acute exposure to tau/tau seeds increased bead uptake 
(Fig. 2C); (iii) Pampuscenko et al. (4) showed that addition of tau to 
cocultures of wild-type neurons and microglia increased phagocytosis 
of the living neurons (via PtdSer exposure) as well as increased 
phagocytosis of beads in pure microglial cultures; and (iv) we do 
not find an effect equivalent to that of 5M P301S neurons using 
neurons from 2M P301S mice, which have not developed aggregates 
and are not engulfed (9). Thus, it is possible that the engulfment of 
a minority of neurons that contain tau aggregates is sufficient for 
the population-level hormetic effect that we observe.
The precise mechanism by which microglia become hormetic 
remains to be resolved. We tested whether PtdSer could be the signal 
since phagocytosis of live neurons by microglia depends on PtdSer 
exposure on the neuronal membrane (4, 9, 41, 42), but hormesis 
was not mimicked by exposure of microglia to PtdSer liposomes, 
nor was MMP3 secretion reduced by masking PtdSer with AnnV. 
Moreover, acidic -galactosidase activity in C57 microglia only 
occurred after exposure to CM from cocultured 5M P301S DRGn 
with microglia. Given that acute exposure to tau monomers or 
aggregates causes an increase in phagocytosis, it seems likely that 
the appearance of hormesis is mediated by other factors released 
into the medium as a result of ingestion of neurons with tau 
aggregates or other factors released due to exposure of microglia to 
tau aggregate–containing neurons, consistent with the SASP profile 
that we observe.
The phenomenon of microglial hormesis after phagocytosis of 
-amyloid has been described previously. For example, microglia 
that have phagocytosed -amyloid fibrils showed reduced phagocy-
tosis toward -amyloid oligomers (43). Hypophagocytic behavior 
Fig. 7. Schematic of proposed microglial dysfunction associated with phagocytosis of tau aggregate–containing neurons. Tau aggregate–containing neurons 
increase reactive oxygen species (ROS) production and expose PtdSer, which recruits cocultured microglia to perform phagocytosis. When phagocytosis occurs, the 
community of microglia undergoes phenotypic transitions characterized by hypophagocytic behavior and the acquisition of senescence-associated traits. Microglia that 
have phagocytosed tau aggregate–containing neurons secrete seeding-competent tau aggregates that can induce further tau aggregation, while paracrine factors can 
convert naïve microglia to become hypophagocytic/senescent-like. The end result is an increasing number of neurons with tau aggregates in a self-amplifying cycle.
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was also observed in  vivo in two mouse models with -amyloid 
plaques (24) and demonstrated by the failure of freshly isolated 
microglia from 5xFAD transgenic mice to clear -amyloid plaques 
from organotypic 5xFAD slice cultures, whereas wild-type microglia 
displayed ample clearance (44). Our data also support the contention 
that microglia in vivo in 5M P301S mice are also hypophagocytic. 
The switch from a pro-resolution phenotype to a hypophagocytic 
phenotype was suggested to represent a proinflammatory state that 
occurs when the microglia fail to digest and degrade engulfed, highly 
stable filamentous protein aggregates (45, 46). However, we did not 
observe a hypophagocytic microglial phenotype when microglia were 
fed with tau aggregates. The molecular differences underpinning 
the different states of the microglia under these different hormetic 
settings remain to be clarified.
In addition to microglia being hypophagocytic, we show that 
coculture of microglia with P301S tau aggregate–containing neurons 
induced the microglia to secrete several senescence-associated 
factors [CXCL1, CXCL2, CCL5, IGFBP3, MMP9, and MMP3 (29)]. 
The presence of dystrophic microglia that have been linked to 
senescence has been reported in AD and other neurodegenerative 
disorders (47–50), although no molecular signatures of senescence 
were recorded. Loss of phagocytic capacity, increased SA--gal 
activity, induction of senescence-associated genes such as CDKN2A/
P19ARF, and altered cytokine profiles such as those we describe 
here are common signs of senescence. In this hypofunctional state, 
microglia may lose their neuroprotective role and possibly exacerbate 
neurodegeneration. The mechanism of transduction to senescence 
is unclear, although both cytokine signaling and phagocytic stress 
have been suggested to induce senescence in retinal epithelium 
(51). It will be important to identify the biochemical mechanism of 
these changes and determine whether modification of the process 
would be beneficial in disease.
The production of MMP3 was one of the most notable changes 
induced by coculture of microglia with 5M P301S neurons. A recent 
transcriptomic analysis (52) describes an anti-inflammatory microglial 
subtype that is induced by inflammation, but this may not resemble 
the response that we observe as none of the proteins that we have 
identified in the CM are present as altered transcripts aside from 
CXCL10 and CCL2, both of which are linked to an inflammasome 
interferon signaling module. A weak link to phagocytosis is the 
up-regulation of ARF and CDC42 transcripts, which modify the 
dynamics of actin polymerization, but with these being more active, 
one may expect more pronounced phagocytosis rather than an 
inhibition such as the one that we observe. Nevertheless, activation 
of MMP3 is a hallmark of several tauopathies, including AD and 
familial FTD cases (53, 54). Since NFB has been implicated in 
control of MMP3 expression in other cell types (31, 55), it was of 
interest to examine to what extent NFB-dependent MMP3 produc-
tion is linked to tau release from cocultured microglia. We found 
that the NFB inhibitor BAY11-7082 prevented MMP3 production 
despite being applied under culture conditions that allow phagocytosis 
of the neurons and therefore release of tau by microglia. An involve-
ment of NFB was corroborated by the presence of phospho-Ser536-
NFB in microglia in 5M P301S mouse brain sections. MMP3 was 
still highly produced in the presence of AnnV, however, which 
blocks phagocytosis. Thus, NFB appears to be activated as a result 
of cell signaling either between neurons with tau aggregates and 
microglia or between post-phagocytosis microglia and surrounding 
microglia. This would also account for the increase in SA--gal–positive 
microglia following exposure to CM from cocultures of microglia 
with P301S DRGn. Since TNF was not induced by the neurons, 
another possible mediator of NFB activation is the reactive oxygen 
species produced by neurons with tau aggregates (19, 56). The 
consequence of such strong up-regulation of an MMP remains to 
be resolved. MMP3 could have effects at the synapse due to its tissue 
remodeling properties via the extracellular matrix and/or by altering 
the chemokine secretome (57–59).
The key message from our study is that microglia switch to an 
alternative, active functional state that is not classically inflammatory as 
a result of coculture of neurons containing tau aggregates. Microglia 
that have phagocytosed tau aggregate–containing neurons produce tau 
seeds, which may enhance tau pathology not only by spreading tau 
aggregation to new neurons but also by contributing to loss of normal 
phagocytic functions throughout the community of microglia.
MATERIALS AND METHODS
Experimental design
The objective of these experiments was to test the functional state 
of microglia after phagocytosis of neurons containing insoluble 
filamentous hyperphosphorylated tau aggregates and to determine 
the fate of the ingested tau. The study was designed as an in vitro cell 
culture system to investigate cellular and biochemical mechanisms 
leading to phenotypic changes in microglia and consequences for 
pathology, confirming key findings using brains from transgenic 
human P301S tau mice and human brain tissue from neurodegen-
erative diseases. We have previously published that DRGn from 
P301S mice with tau aggregates expose PtdSer and are phagocytosed 
live by cocultured microglia (9).
Mice
Homozygous mice transgenic for human 0N4R P301S tau (18) 
(henceforth P301S) and C57BL/6S (C57BL/6OlaHsd; henceforth 
C57) control mice were maintained as described previously (17). 
P301S tau mice were aged to 5 months, when phenotype is evident. 
Each independent experiment (N) was derived from an independent 
culture from an individual mouse. This research project was performed 
under the Animals (Scientific Procedures) Act 1986, Amendment 
Regulations 2012 following ethical review by the University of 
Cambridge Animal Welfare and Ethical Review Body. Both female 
and male mice were used for experiments. Mice were housed in 
groups in individually ventilated cages, adding a plastic roll and 
nesting material for enrichment. Mice were kept under a 12-hour 
light/dark cycle, with food and water available ad libitum.
Human tissue
Human tissue was obtained from the Cambridge Brain Bank and 
the Alzheimer’s Center at Indiana University. Handling of human 
tissue was according to the U.K. Human Tissue Act 2006 and is covered 
by the Cambridge Local Research Ethics Committee, approval 
number 04/090. Each case was neuropathologically confirmed as 
being either control, Pick’s disease, PSP, or expressing mutant P301L 
or +3 or C9ORF72 as described previously (9). The cohort contained 
mixed sexes, and the age at death ranged from 53 to 76 (full details 
in table S1). Fresh-frozen frontal cortex or midbrain was homogenized 
in radioimmunoprecipitation assay containing 2.5% SDS with 
protease inhibitors (Roche) at a ratio of 1:2 (w/v) with an IKA T-10 
Ultra Turrax. Whole homogenates were clarified by centrifugation 
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at 20,000g for 30 min at 4°C. The protein content in the resulting 
supernatant was determined by bicinchoninic acid (BCA) assay 
(Pierce), and 5 g of protein was analyzed by immunoblot.
Cell cultures
DRGn from either P301S or C57 mice were cultured either on 
six-well culture plates coated with poly-d-lysine or laminin and 
maintained as reported previously (17). To visualize tau aggregates, 
neurons were labeled in medium containing 3 M pFTAA (a gift 
from K. P. R. Nilsson, Linköping University, Sweden, as previously 
described). Primary microglial cells were prepared from postnatal 
day 2 to 4 pups as previously described and cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 1% Antibiotic- 
Antimycotic (PSF) (Thermo Fisher Scientific, 15240062) and 2 mM 
GlutaMAX (Gibco, 35050061) (henceforth DMEM/PSF/Gmax), 10% 
heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific, 
10082147), and mCSF1 (50 ng/ml; Peprotech, 315-02). For cocul-
ture experiments, 5M P301S or C57 DRGn were cultured for 7 days 
in DMEM/PSF/Gmax containing 1% heat-inactivated FBS and 20 M 
fluorodeoxyuridine to remove non-neuronal cells. After washing the 
DRGn in phosphate- buffered saline (PBS), 200,000 primary microglia 
were added directly to the neurons, and mixed cultures were main-
tained in DMEM/PSF/Gmax and 5% heat-inactivated FBS for 4 days 
at which time the CM was collected. For transfer experiments, 
microglia were reisolated from the first coculture by physical dissoci-
ation in ice-cold PBS without Mg2+ or Ca2+, passed through a 40-m-
pore membrane to exclude any contaminating DRGn, and added to 
a fresh culture of P301S DRGn in the same medium containing 5% 
heat-inactivated FBS for a further 4 days. For testing bead uptake and 
SA--gal activity, reisolated microglia were plated onto glass covers-
lips for 4 days in microglial growth medium containing mCSF1 
(10 ng/ml). NFB inhibition in microglia was performed by adding 
5 M BAY11-7082 (Sigma-Aldrich, B5556) for 1 hour before 
microglial addition to DRGn. AnnV (100 nM) (ImmunoTools, 
31490010) was added to the DRGn to pretreat and mask PtdSer, 
thus preventing phagocytosis.
Seeding assay
HEK-P301S-venus cells were maintained in DMEM, 10% FBS, and 
1% PSF on 13-mm uncoated glass coverslips. To assay the tau 
aggregate seeding efficiency of CM, maintenance medium was 
replaced with CM for 48 hours in the absence or presence of 
Lipofectamine 2000 diluted 1:100 (21). Cells were then fixed in 4% 
paraformaldehyde (PFA) and immunostained as below.
Immunocytochemistry
Tau aggregates in P301S DRGn were labeled live with pFTAA as 
described previously (19, 23). To detect and quantify the number of 
neurons with htau, neurons were costained with anti–htau mono-
clonal antibody HT7 (1:500; Thermo Fisher Scientific, MN1000) 
and anti–III-tubulin (1:1000; Sigma-Aldrich, T2200). Between 
100 and 200 neurons were counted along a strip that extended 
from the top to the bottom of a 13-mm coverslip using a 10× objective 
(about 10 fields) in each independent culture for determining the 
ratio of HT7/III-tubulin. Reisolated microglia were counterstained 
with DAPI (4′,6-diamidino-2-phenylindole) and/or phalloidin-Alexa 
Fluor-647 (Life Technologies) and then mounted in FluorSave 
(Millipore). HEK-P301S-venus cells were permeabilized in 0.3% 
Triton X in PBS (PBST) and incubated with primary antibody 
overnight in PBST using AT8 antibody (1:1000; Thermo Fisher Sci-
entific, MN1020), to detect hyperphosphorylated tau, and MC1, as 
described previously (23). Cells on coverslips were washed in PBS 
and incubated with appropriate Alexa Fluor-conjugated secondary 
antibody for 1 hour at room temperature in PBST, counterstained 
with DAPI (0.1 g/ml), and mounted in FluorSave. For staining of 
brain sections with anti-phospho-Ser536 NFB antibody (1:500; Cell 
Signaling, 3031S), 25-m sections of 5M P301S or 5M C57 mouse 
cortices that had been postfixed in 4% PFA (19, 23) were stained 
overnight at 4°C with primary antibody in PBST followed by 
anti-rabbit biotinylated antibody (1:500; Vectorlabs, BA-1000) and 
streptavidin-conjugated Alexa Fluor-568. To colocalize staining 
with microglia, sections were stained with goat anti-Iba1 (1:250; 
Abcam, ab5076) followed by anti-goat Alexa Fluor-647. Sections 
were then stained with 3 M pFTAA and DAPI (0.1 g/ml). Images 
were taken on a Leica DMI 4000B microscope using a Leica 
DFC3000 G camera and the Leica application suite 4.0.0.11706. 
Images were analyzed using ImageJ (Rasband, W.S., ImageJ, U.S. 
National Institutes of Health, Bethesda, MD, USA; http://imagej.
nih.gov/ij/). Micrographs of each fluorescence channel were used 
to count neurons with ImageJ cell counter plugin. P19ARF/CDKN2 
antibody (1:500; Novus, NB200-106) was applied to fixed microglia and 
visualized using anti-rabbit Alexa Fluor-568. Microglial perimeters were 
defined using the lectin IB4 conjugated to fluorescein isothiocyanate 
(Vectorlabs, FL-1201-.5). Nuclear P19ARF intensity was quantified 
using ImageJ to measure pixel intensity and nuclear area.
Enzyme-linked immunosorbent assay
DRGn from P301S or C57 mice were cocultured with C57 microglia 
for 4 days to generate CM where tau was assayed. CM was first 
centrifuged at 20,000g for 20 min to remove any cellular debris, and 
the supernatant was collected. Tau protein concentration in CM was 
assayed with anti–htau ELISA according to the manufacturer’s 
instructions (Abcam, ab210972). LDH assay was performed on the CM 
according to the manufacturer’s instructions (Abcam, ab102526). To assay 
the effect of NFB inhibition, DRGn from P301S or C57 were cocul-
tured with C57 microglia that had been pretreated with BAY11-7082 or 
left untreated for 24 hours to generate CM for MMP3 assay. MMP3 
ELISA (Abcam, ab100731) was performed on CM 24  hours after 
addition of microglia according to the manufacturer’s instructions.
Immunoblotting
Cells were lysed in 1% NP-40, 137 mM NaCl, 2 mM EDTA, and 
20 mM tris-HCl (pH 8) with protease inhibitor cocktail (Roche, 
04693116001) and assayed for protein concentration by the BCA 
assay (Pierce, 23225). Equal protein amounts were added to Lithium 
dodecyl sulfate (LDS) loading buffer (Bio Rad 161-0747) containing 
10% -mercaptoethanol and run on 4 to 12% gradient SDS–poly-
acrylamide gel electrophoresis gels. Proteins were transferred 
onto 0.2-m-pore polyvinylidene difluoride membranes (Merck, 
IPVH00010). Nonspecific background was blocked in 5% (w/v) dry 
skimmed milk (Sigma-Aldrich) in PBS containing 0.1% Tween 20, 
and membranes were incubated with the primary antibody (Abcam, 
ab53015) overnight at 4°C, followed by 1 hour at room temperature 
in the appropriate horseradish peroxidase–labeled secondary anti-
body (GE Healthcare). Blots were developed with enhanced che-
miluminesence Clarity (Bio-Rad, 1705061). Intensity was quantified 
using ImageJ. In mouse samples, the ratio of pro to active MMP3 was 
used to express the percentage of active MMP3, but the ratio of active 
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MMP3 to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was used for human samples because no pro-MMP3 was detected in 
some samples.
Membrane filtration assay
CMs were centrifuged at 20,000g for 20 min to remove cellular 
debris. Cellulose acetate membranes (0.2 m) were soaked in 5% SDS 
in dH2O for 10 min at room temperature and then mounted onto a 
96-well vacuum chamber. Samples were incubated in 5% SDS in 
dH2O for 10 min at room temperature, and 2 ml of each CM was 
filtered through the membrane under vacuum. Membranes were 
washed in 5% SDS under vacuum, rinsed in PBS and 0.1% Tween 20, 
then incubated with primary antibody (HT7; 2 g/ml) overnight 
at 4°C, and developed using the method described for immunoblotting. 
A sarkosyl-insoluble extract from a 5-month-old P301S mouse spinal 
cord prepared as described previously (18) was the positive control. 
After initial signal development, each membrane dot was cut out of 
the membrane and bisected; half was treated with 70% FA for 
15  min and then dialyzed overnight with Slide-A-Lyzer (Thermo 
Fisher Scientific, 66203) in PBS and 0.1% Tween 20. The other half 
was minced, vortexed, and soaked in 5% SDS to elute available 
captured protein. Processed samples were then membrane-filtered, 
antibody-incubated, and developed as before.
Latex bead phagocytosis assays
To assay phagocytic activity in cell culture, fluorescent latex carboxylate- 
modified polystyrene beads (2.0 m mean particle size) were added 
to reisolated microglial cultures on 13-mm coverslips at 1:10,000 
dilution for 12  hours at 37°C or added to cultures of matched 
cohorts pretreated with either LPS (100 ng/ml) for 1 hour, 12 nM 
monomeric tau, 12 nM heparin-fibrillized tau (monomer equiva-
lent), or PtdSer vesicles (1 g/ml) prepared by dissolving PtdSer in 
chloroform and drying under nitrogen before hydration in PBS and 
sonication to produce a vesicle suspension. Cultures were washed in 
PBS to remove free beads and fixed in 4% PFA. Microglia were 
counterstained with DAPI and phalloidin-Alexa Fluor-647 and 
mounted with FluorSave. Images were collected using the Leica 
DMI 4000B microscope and analyzed using ImageJ.
To assay the phagocytic activity of microglia in acute brain 
sections, fresh brains from 5M C57 or P301S mice were immediately 
submerged in ice-cold N-methyl-d-glucosamine (NMDG) artificial 
cerebrospinal fluid (aCSF) (60). The brains were bisected along the 
midline, and both hemispheres were mounted together (medial sur-
faces down) on the cutting stage of a Leica VT1200S vibratome with 
superglue. Sequential 130-m sections were generated (amplitude: 
0.7 m; speed: 0.7 m/s). Anatomically matched pairs of slices were 
collected in a 24-well plate containing 500 l per well of ice-cold 
NMDG-aCSF, with one slice per well. Slices were left to recover in 
the incubator (5% CO2, 37°C) for 2 hours, after which 2-m fluores-
cent latex beads were added into the medium of one set of slices at a 
1:100 dilution and left for 3 hours. The other matching sets of slices 
were kept without beads. Sections were thoroughly washed in PBS 
to remove free beads and fixed in 4% PFA. All sections were stained 
overnight at 4°C with goat anti-Iba1 antibody (1:500, Abcam, 
ab5076) to assess microglial colocalization. The sections incubated 
with beads were stained with an Alexa Fluor-488 anti-goat sec-
ondary antibody (1:500) in PBST, while the sections without beads 
were stained with an Alexa Fluor-647 anti-goat secondary antibody 
(1:500) for 1  hour at room temperature, followed by staining 
with pFTAA (3 M). All sections were stained with DAPI (1 g/ml). 
Sections were mounted with Fluoromount-G. Images for quantifi-
cation were collected using a Leica DMI 4000B microscope and 
analyzed using ImageJ. Phagocytic index was computed as described 
previously (24). Briefly, the number of beads per cell counts was 
stratified into bins of 1 to 4, 5 to 7, 8 to 10, and >10. Each bin was 
assigned a corresponding weight (1 to 4:1, 5 to 7:2, 8 to 10:3, and 
>10:4). For each mouse, the percentage of cells within each bin was 
multiplied by the weight of the corresponding bin, which was then 
summed and displayed as the phagocytic index.
SA--gal assay
Reisolated microglia were plated onto 13-mm coverslips and fixed 
in 4% PFA. The activity of -galactosidase at pH 6.0 was assayed in 
a staining solution consisting of 5-bromo-4-chloro-3-indolyl--d- 
galactopyranoside (1 mg/ml; X-gal; Invitrogen, AM9944), 10 mM 
citrate-sodium phosphate buffer (pH 6.0), 5 mM potassium ferricy-
anide, 5 mM potassium ferrocyanide, 150 mM NaCl, and 2 mM 
MgCl2 overnight (18 to 20 hours) at 37°C. Bleomycin (50 g/ml) was 
added as a positive control inducer of chemical senescence for 
12 hours. Coverslips were washed and mounted in FluorSave. For 
CM treatments, CMs from five independent cocultures of microglia 
with 5M C57 or 5M P301S neurons or monocultures of the same 
neuron preparations were added to a single preparation of C57 
microglia on coverslips for 4 days. Cultures were fixed, stained, and 
mounted as per reisolated microglia. For brain sections, 25-m 
floating brain sections that had been postfixed in 4% PFA were 
incubated in the X-gal mixture for 18 hours at 37°C; pFTAA staining 
was used to verify P301S tau pathology. Colorimetric X-gal staining 
was imaged using an Olympus BX50 microscope and QCapture Pro 
7 QImaging suite with a Retiga 2000R Fast 1394 camera.
Cytokine array
CM was collected and centrifuged at 20,000g to remove cellular 
debris. Comparative cytokine amounts were assayed with the 
proteome profiler XL mouse cytokine array as per the manufacturer’s 
instructions (R&D, ARY028). Densitometric measurements were 
quantified using ImageJ and normalized between membranes using 
the membranes’ positive controls. To identify expression pathways, 
the data were analyzed by STRING analysis [(28), https://string-db.
org/]. Interactions permitted were experimentally determined, 
coexpressed, and those that were predicted to be expressed by 
databases; any noninteracting proteins were removed from the 
analysis. Selecting the most confident partner interactions in the 
remaining array (threshold, ≥0.9) yielded the following unique 
proteins: CXCL9, CXCL10, CXCL5, CXCL2, CXCL1, CCL5, CCL20, 
ENDOSTATIN, VEGFA, MMP2, CXCL13, IGFBP3, MMP9, PTX3, 
and MMP3. Cxcl5, Cxcl9, Cxcl13, and Ccl20 were omitted due to 
lack of detectable secretion across all conditions. The abundance of 
11 proteins across three independent biological replicates was 
expressed as a mean. The raw abundance values were standardized 
by calculating z scores for each protein across all conditions, such 
that 0 represents the group mean, and each SD from the mean is 
represented by integer values (e.g., −2, −1, 1, and 2). These results 
were then displayed on a heatmap.
Principal components analysis
PCA was conducted using the Scikit-Learn library in Python 
(version 3.7.6) (61). To calculate error bars (SD), full replicate 
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data (n = 3) were used to “train” the PCA transformation matrix, 
and error was calculated for each condition from the PC1 and 
PC2 coordinates of the replicates. This same transformation 
matrix was then applied to the mean-only dataset, and the error 
bars calculated previously were interpolated onto each correspond-
ing condition.
Statistical analysis
Statistical analysis and graphing were performed using GraphPad 
Prism version 7. Samples were compared using normal or repeated- 
measures ANOVA followed by an appropriate post hoc test or by 
Student’s t test as indicated. A one-sample t test was used when a 
mean was compared to a hypothesized mean value of zero because 
the measurement was below the level of detection. Repeated-measures 
ANOVA with matched pairs was specifically applied when comparing 
different culture conditions on the same sample source. Mann-Whitney 
U test was used for the acute brain section bead phagocytosis assay, 
as the data were not normally distributed (Shapiro-Wilk test). An 
independent experiment is defined as being sourced from a single 
animal. Significant differences are reported as *P < 0.05, **P < 0.01, 
***P < 0.001, and ****P < 0.0001.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abg4980
View/request a protocol for this paper from Bio-protocol.
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